| Stereochemistry | ABSOLUTE |
| Molecular Formula | C35H60O6 |
| Molecular Weight | 576.8473 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 14 / 14 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]1(CC[C@@]2([H])[C@]3([H])CC=C4C[C@H](CC[C@]4(C)[C@@]3([H])CC[C@]12C)O[C@]5([H])O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)[C@H](C)CC[C@@H](CC)C(C)C
InChI
InChIKey=NPJICTMALKLTFW-OFUAXYCQSA-N
InChI=1S/C35H60O6/c1-7-22(20(2)3)9-8-21(4)26-12-13-27-25-11-10-23-18-24(14-16-34(23,5)28(25)15-17-35(26,27)6)40-33-32(39)31(38)30(37)29(19-36)41-33/h10,20-22,24-33,36-39H,7-9,11-19H2,1-6H3/t21-,22-,24+,25+,26-,27+,28+,29-,30-,31+,32-,33-,34+,35-/m1/s1
SITOGLUSIDE (Daucosterol) inhibits cancer cell proliferation by inducing autophagy through reactive oxygen species-dependent manner. It also perturbs cell cycle and induces apoptotic cell death in A549 cells. Daucosterol has being shown to promote the proliferation of neural stem cells. Daucosterol also protects neurons against oxygen-glucose deprivation/reperfusion-mediated injury by activating IGF1 signaling pathway. Daucosterol could be potentially developed as a medicine for ischemic stroke treatment.
Originator
Approval Year
PubMed
Patents
Sample Use Guides
Mice: 0.5mg/kg daucosterol significantly inhibit the H22 tumor growth in vivo (0.71±0.29 g vs 1.51±0.23 g in control grroup). Moreover, 2.5mg/kg daucosterol treatment further lowered the tumor weight to 0.46±0.28g (p<0.01).
Route of Administration:
Oral
ACTIVE MOIETY
